Vokanamet

canagliflozin / metformin

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Vokanamet. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vokanamet.

For practical information about using Vokanamet, patients should read the package leaflet or contact their doctor or pharmacist.

: Vokanamet is a diabetes medicine that contains the active substances canagliflozin and metformin. It is used, together with diet and exercise, to control the blood glucose (sugar) levels in adults with type 2 diabetes whose disease is not satisfactorily controlled with metformin alone, or in combination with other diabetes medicines, including insulin, when these medicines together with metformin are not providing adequate control of the diabetes. Vokanamet can also be used to replace canagliflozin and metformin given separately.

: Vokanamet is available as tablets containing canagliflozin and metformin in various strengths (50/850 mg, 150/850 mg, 50/1000 mg and 150/1000 mg) and can only be obtained with a prescription.
The recommended dose is one tablet taken twice a day. The tablet strength depends on the patient’s treatment before starting Vokanamet. Patients should start Vokanamet at a strength that provides 50 mg canagliflozin and the dose of metformin they were previously taking (or a close approximation of it). The dose of canagliflozin can then be increased if needed.
When Vokanamet is used as an add-on to insulin or medicines that stimulate the secretion of insulin (e.g. sulphonylureas) the dose of these other medicines may need to be reduced to lower the risk of the patient’s blood glucose becoming too low.
For further information, see the package leaflet.

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. This leads to high levels of glucose in the blood.

Vokanamet contains two different active substances, which work in different ways:

canagliflozin works by blocking a protein in the kidneys called sodium glucose co-transporter 2 (SGLT2). SGLT2 absorbs glucose back into the bloodstream as the blood is filtered in the kidneys. By blocking the action of SGLT2, canagliflozin causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood. Canagliflozin as separate tablets has been authorised in the EU under the brand name Invokana since 15 November 2013.
Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut. It has been available in the EU since the 1950s.

As a result of the action of both active substances, the blood glucose is reduced and this helps to control type 2 diabetes.

: The benefits of canagliflozin used in combination with metformin have been shown in several main studies that were evaluated at the time of the authorisation of Invokana. The studies, involving over 5,000 adults with type 2 diabetes, studied canagliflozin at daily doses of 100 and 300 mg and looked mainly at how they reduced the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
In two studies evaluating canagliflozin as an add-on to metformin, the reductions in HbA1c levels after 26 weeks was 0.91 to 1.16 percentage points higher with canagliflozin than with placebo (a dummy treatment) when added to metformin and canagliflozin achieved similar reductions to two other diabetes medicines, glimepiride and sitagliptin, after 52 weeks of treatment.
Three further studies evaluated canagliflozin as an add-on to combined treatment with metformin and either a sulphonylurea or pioglitazone. Added to metformin and a sulphonylurea, canagliflozin led to reductions in HbA1c that were between 0.71 and 0.92percentage points more than those seen with placebo after 26 weeks and similar to those seen with sitagliptin (another diabetes medicine) after 52 weeks. Added to metformin and pioglitazone, canagliflozin was also superior to placebo, leading to HbA1c reductions that were 0.62 and 0.76 points more than was seen by adding placebo.
Canagliflozin was also studied as an add-on treatment in patients who were taking insulin alone, or insulin in combination with other diabetes medicines including metformin and in patients who were taking a sulphonylurea. Adding canagliflozin to treatment was shown to be effective at reducing HbA1c compared with placebo by 0.65 to 0.73 points after 18 weeks in patients receiving insulin and by 0.74 to 0.83 points in patients receiving a sulphonylurea.

The most common side effects with Vokanamet (which may affect more than 1 in 10 people) are hypoglycaemia (low blood glucose levels) when used in combination with insulin or a sulphonylurea and vulvovaginal candidiasis (thrush, a fungal infection of the female genital area caused by Candida).

Vokanamet must not be used in:

patients with diabetic ketoacidosis or pre-coma (dangerous complications of diabetes),
patients with moderately or severely reduced kidney function or with severe conditions that could affect the kidneys such as dehydration or severe infection.
patients with a condition that could lead to body tissues being deprived of oxygen (e.g. heart or respiratory failure)
patients who have liver impairment or are suffering from alcoholism or are intoxicated.

For the full list of restrictions, see the package leaflet.

: The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vokanamet’s benefits are greater than its risks and recommended that it be approved for use in the EU. The benefits of metformin are well established and the added advantage of adding canagliflozin to metformin to control blood sugar has been shown in the studies. It also leads to weight loss, which is considered beneficial in patients with diabetes. The CHMP also noted that giving the combination of canagliflozin and metformin as a single tablet could provide an additional treatment option for patients with type 2 diabetes, and may improve adherence to treatment.
Concerning its safety, the CHMP considered that the side effects seen with Vokanamet are acceptable and can be managed in clinical practice.

: A risk management plan has been developed to ensure that Vokanamet is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vokanamet, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the risk-management-plan summary.

: The European Commission granted a marketing authorisation valid throughout the European Union for Vokanamet on 23 April 2014.
For more information about treatment with Vokanamet, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

List item

Vokanamet : EPAR - Summary for the public (PDF/84.72 KB)

First published: 15/05/2014
Last updated: 15/05/2014
EMA/119828/2014
- Bulgarian
  (PDF/114.38 KB)
- Croatian
  (PDF/104.25 KB)
- Czech
  (PDF/111.02 KB)
- Danish
  (PDF/85.54 KB)
- Dutch
  (PDF/85.62 KB)
- Estonian
  (PDF/84.2 KB)
- Finnish
  (PDF/83.98 KB)
- French
  (PDF/101.7 KB)
- German
  (PDF/87.43 KB)
- Greek
  (PDF/115.19 KB)
- Hungarian
  (PDF/107.64 KB)
- Italian
  (PDF/84.43 KB)
- Latvian
  (PDF/108.75 KB)
- Lithuanian
  (PDF/110.12 KB)
- Maltese
  (PDF/112.31 KB)
- Polish
  (PDF/113.47 KB)
- Portuguese
  (PDF/85.66 KB)
- Romanian
  (PDF/110.21 KB)
- Slovak
  (PDF/111.96 KB)
- Slovenian
  (PDF/106.47 KB)
- Spanish
  (PDF/84.27 KB)
- Swedish
  (PDF/83.57 KB)
List item

Vokanamet : EPAR - Risk-management-plan summary (PDF/103.09 KB) (updated)

First published: 15/05/2014
Last updated: 27/02/2023

This EPAR was last updated on 27/02/2023

Authorisation details

Product details
Name	Vokanamet
Agency product number	EMEA/H/C/002656
Active substance	canagliflozin metformin hydrochloride
International non-proprietary name (INN) or common name	canagliflozin metformin
Therapeutic area (MeSH)	Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code	A10BD16

Publication details
Marketing-authorisation holder	Janssen-Cilag International NV
Revision	20
Date of issue of marketing authorisation valid throughout the European Union	23/04/2014
Contact address	Turnhoutseweg 30 B-2340 Beerse Belgium

Product information

24/02/2023 Vokanamet - EMEA/H/C/002656 - N/0068

List item

Vokanamet : EPAR - Product Information (PDF/493.46 KB) (updated)

First published: 15/05/2014
Last updated: 27/02/2023
- Bulgarian
  (PDF/559.89 KB)
- Croatian
  (PDF/526.51 KB)
- Czech
  (PDF/649.91 KB)
- Danish
  (PDF/498.23 KB)
- Dutch
  (PDF/468.9 KB)
- Estonian
  (PDF/515.77 KB)
- Finnish
  (PDF/503 KB)
- French
  (PDF/521.87 KB)
- German
  (PDF/452.41 KB)
- Greek
  (PDF/451.67 KB)
- Hungarian
  (PDF/451.88 KB)
- Icelandic
  (PDF/680.12 KB)
- Italian
  (PDF/492.36 KB)
- Latvian
  (PDF/865.25 KB)
- Lithuanian
  (PDF/562.45 KB)
- Maltese
  (PDF/584.36 KB)
- Norwegian
  (PDF/512.28 KB)
- Polish
  (PDF/544.35 KB)
- Portuguese
  (PDF/501.67 KB)
- Romanian
  (PDF/488.27 KB)
- Slovak
  (PDF/445.27 KB)
- Slovenian
  (PDF/522.78 KB)
- Spanish
  (PDF/510.93 KB)
- Swedish
  (PDF/530.38 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Vokanamet : EPAR - All Authorised presentations (PDF/29.75 KB)

First published: 15/05/2014
Last updated: 15/05/2014
- Bulgarian
  (PDF/30.75 KB)
- Croatian
  (PDF/28.46 KB)
- Czech
  (PDF/29.24 KB)
- Danish
  (PDF/29.33 KB)
- Dutch
  (PDF/28.17 KB)
- Estonian
  (PDF/30.71 KB)
- Finnish
  (PDF/29.77 KB)
- French
  (PDF/28.71 KB)
- German
  (PDF/28.85 KB)
- Greek
  (PDF/32.37 KB)
- Hungarian
  (PDF/28.95 KB)
- Icelandic
  (PDF/30.2 KB)
- Italian
  (PDF/28.81 KB)
- Latvian
  (PDF/30.73 KB)
- Lithuanian
  (PDF/28.46 KB)
- Maltese
  (PDF/45.61 KB)
- Norwegian
  (PDF/29.42 KB)
- Polish
  (PDF/30.68 KB)
- Portuguese
  (PDF/29.28 KB)
- Romanian
  (PDF/30.83 KB)
- Slovak
  (PDF/31.01 KB)
- Slovenian
  (PDF/27.96 KB)
- Spanish
  (PDF/28.56 KB)
- Swedish
  (PDF/27.64 KB)

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

in patients not adequately controlled on their maximally tolerated doses of metformin alone
in patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control.
in patients already being treated with the combination of canagliflozin and metformin as separate tablets

For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Assessment history

Changes since initial authorisation of medicine

List item

Vokanamet : EPAR - Procedural steps taken and scientific information after authorisation (PDF/268.39 KB) (updated)

First published: 23/12/2014
Last updated: 27/02/2023
List item

Vokanamet-H-C-PSUSA-00010077-201903 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/121.04 KB)

First published: 18/02/2020
EMA/67311/2020
List item

Vokanamet-H-A20-1442-C-2656-0014 : EPAR - Assessment Report - Article 20 (PDF/254.07 KB)

Adopted

First published: 05/07/2017
Last updated: 05/07/2017
EMA/PRAC/637349/2016
List item

Vokanamet-H-A20-1442-C-2656-0014 : EPAR - Scientific Conclusion - Article 20 (PDF/41.36 KB)

First published: 05/07/2017
Last updated: 05/07/2017
- Bulgarian
  (PDF/84.18 KB)
- Croatian
  (PDF/76.27 KB)
- Czech
  (PDF/78.08 KB)
- Danish
  (PDF/41.03 KB)
- Dutch
  (PDF/42.37 KB)
- Estonian
  (PDF/40.46 KB)
- Finnish
  (PDF/40.53 KB)
- French
  (PDF/42.93 KB)
- German
  (PDF/44.39 KB)
- Greek
  (PDF/84.71 KB)
- Hungarian
  (PDF/60.56 KB)
- Icelandic
  (PDF/40.74 KB)
- Italian
  (PDF/40.72 KB)
- Latvian
  (PDF/76.13 KB)
- Lithuanian
  (PDF/72.25 KB)
- Maltese
  (PDF/83.36 KB)
- Norwegian
  (PDF/40.5 KB)
- Polish
  (PDF/62.96 KB)
- Portuguese
  (PDF/42.06 KB)
- Romanian
  (PDF/78.32 KB)
- Slovak
  (PDF/70.79 KB)
- Slovenian
  (PDF/75.63 KB)
- Spanish
  (PDF/41.99 KB)
- Swedish
  (PDF/41.68 KB)
List item

Vokanamet-H-C-2656-A-31-1432 : EPAR - Assessment Report - Article 31 (PDF/569.41 KB)

Adopted

First published: 21/12/2016
Last updated: 21/12/2016
EMA/CHMP/539626/2016 Corr. 2
List item

Vokanamet-H-C-2656-A-31-1432 : EPAR - Scientific Conclusion (PDF/39.25 KB)

First published: 21/12/2016
Last updated: 21/12/2016
- Bulgarian
  (PDF/74.64 KB)
- Croatian
  (PDF/67.76 KB)
- Czech
  (PDF/71.74 KB)
- Danish
  (PDF/34.42 KB)
- Dutch
  (PDF/35.24 KB)
- Estonian
  (PDF/33.82 KB)
- Finnish
  (PDF/34.48 KB)
- French
  (PDF/38.92 KB)
- German
  (PDF/36.94 KB)
- Greek
  (PDF/73.87 KB)
- Hungarian
  (PDF/53.21 KB)
- Icelandic
  (PDF/35.49 KB)
- Italian
  (PDF/34.17 KB)
- Latvian
  (PDF/70.28 KB)
- Lithuanian
  (PDF/70.29 KB)
- Maltese
  (PDF/72.42 KB)
- Norwegian
  (PDF/33.35 KB)
- Polish
  (PDF/54.65 KB)
- Portuguese
  (PDF/35.06 KB)
- Romanian
  (PDF/68.99 KB)
- Slovak
  (PDF/56.7 KB)
- Slovenian
  (PDF/66.05 KB)
- Spanish
  (PDF/35.06 KB)
- Swedish
  (PDF/35.08 KB)
List item

Vokanamet-H-C-2656-A20-1419-0007 : EPAR - Assessment Report - Article 20 (PDF/264.09 KB)

Adopted

First published: 19/05/2016
Last updated: 19/05/2016
EMA/PRAC/50218/2016
List item

Vokanamet-H-C-2656-A20-1419-0007 : EPAR - Scientific Conclusion (PDF/44.81 KB)

First published: 19/05/2016
Last updated: 19/05/2016
- Bulgarian
  (PDF/105.04 KB)
- Croatian
  (PDF/97.6 KB)
- Czech
  (PDF/103.45 KB)
- Danish
  (PDF/70.2 KB)
- Dutch
  (PDF/69.79 KB)
- Estonian
  (PDF/68.08 KB)
- Finnish
  (PDF/68.79 KB)
- French
  (PDF/70.95 KB)
- German
  (PDF/73.08 KB)
- Greek
  (PDF/106.77 KB)
- Hungarian
  (PDF/90.13 KB)
- Italian
  (PDF/68.54 KB)
- Latvian
  (PDF/97.56 KB)
- Lithuanian
  (PDF/103.13 KB)
- Maltese
  (PDF/106.45 KB)
- Polish
  (PDF/92.49 KB)
- Portuguese
  (PDF/69.87 KB)
- Romanian
  (PDF/102.42 KB)
- Slovak
  (PDF/100.77 KB)
- Slovenian
  (PDF/97.25 KB)
- Spanish
  (PDF/70.05 KB)
- Swedish
  (PDF/70.67 KB)
List item

Vokanamet-H-C-PSUSA-00010077-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/67.94 KB)

First published: 29/01/2016
Last updated: 29/01/2016
EMA/766817/2015
List item

Vokanamet-H-C-PSUSA-00010077-201411 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/75.56 KB)

First published: 29/09/2015
Last updated: 29/09/2015
EMA/602251/2015

Vokanamet

Table of contents

Overview

Vokanamet : EPAR - Summary for the public (PDF/84.72 KB)

Vokanamet : EPAR - Risk-management-plan summary (PDF/103.09 KB) (updated)

Authorisation details

Product information

Vokanamet : EPAR - Product Information (PDF/493.46 KB) (updated)

Vokanamet : EPAR - All Authorised presentations (PDF/29.75 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Vokanamet : EPAR - Procedural steps taken and scientific information after authorisation (PDF/268.39 KB) (updated)

Vokanamet-H-C-PSUSA-00010077-201903 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/121.04 KB)

Vokanamet-H-A20-1442-C-2656-0014 : EPAR - Assessment Report - Article 20 (PDF/254.07 KB)

Vokanamet-H-A20-1442-C-2656-0014 : EPAR - Scientific Conclusion - Article 20 (PDF/41.36 KB)

Vokanamet-H-C-2656-A-31-1432 : EPAR - Assessment Report - Article 31 (PDF/569.41 KB)

Vokanamet-H-C-2656-A-31-1432 : EPAR - Scientific Conclusion (PDF/39.25 KB)

Vokanamet-H-C-2656-A20-1419-0007 : EPAR - Assessment Report - Article 20 (PDF/264.09 KB)

Vokanamet-H-C-2656-A20-1419-0007 : EPAR - Scientific Conclusion (PDF/44.81 KB)

Vokanamet-H-C-PSUSA-00010077-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/67.94 KB)

Vokanamet-H-C-PSUSA-00010077-201411 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/75.56 KB)

Initial marketing-authorisation documents

Vokanamet : EPAR - Public assessment report (PDF/2.51 MB)

CHMP summary of positive opinion for Vokanamet (PDF/69.15 KB)

News

More information on Vokanamet

Questions and answers on the use of Vokanamet in diabetic kidney disease (PDF/133.57 KB)

Related content

How useful was this page?